Drug Watch

New clinical trial results reveal BPL-003's rapid and durable antidepressant effects, paving the way for innovative treatments in treatment-resistant depression.

The FDA will update ADHD medication labels, warning of weight loss risks in children under 6, urging careful monitoring by health care professionals.

Check out the pipeline updates from June!

Alto Neuroscience's ALTO-203 trial reveals mixed results, highlighting potential biomarkers for targeted depression treatment despite missing primary efficacy goals.

Compass Pathways reports significant progress in psilocybin research, showing promise for treatment-resistant depression in a pivotal phase 3 trial.

NRx Pharmaceuticals advances NRX-100, a preservative-free ketamine, through a fast-tracked FDA review for treating suicidal depression and PTSD.

Ecopipam shows promise as a safe, effective treatment for Tourette syndrome in children and adolescents, significantly reducing tic severity and improving quality of life.

The FDA's removal of clozapine REMS enhances access to treatment, while new educational initiatives empower clinicians to improve patient care.

The RECOVER open label trial demonstrated positive results for brilaroxazine for schizophrenia.

Check out the pipeline updates from May!

Cariprazine shows promise as a long-term adjunctive treatment for anhedonia in major depressive disorder, according to new poster data presented at the ASCP Annual Meeting.

Neurocrine Biosciences reveals promising phase 2 results for NBI-1117568, a novel treatment for schizophrenia, showing significant symptom improvement over placebo.

Promising results from a phase 2 study of CPL'36, a novel PDE10A inhibitor, for acute schizophrenia exacerbation was presented at the APA annual meeting.

Dana Hilt, MD, PhD, discusses data on Xanamem’s impact on cortisol and its potential use in MDD at the APA Annual Meeting.

New analyses reveal valbenazine (Ingrezza) significantly enhances quality of life and functional outcomes for patients with tardive dyskinesia, supporting its long-term efficacy.

Newron Pharmaceuticals launches pivotal ENIGMA-TRS trials for evenamide, targeting treatment-resistant schizophrenia with promising efficacy and safety outcomes.

Adial Pharmaceuticals advances its treatment for alcohol use disorder, AD04, with FDA meetings and promising genetic insights for targeted therapy.

NRx Pharmaceuticals secures FDA fee waiver for NRX-100, a preservative-free ketamine aimed at treating suicidal depression, enhancing accessibility for patients.

Check out the pipeline updates from April!

A groundbreaking study explores innovative neuroassessment technology to enhance understanding and treatment of borderline personality disorder symptoms.

Peter J. Weiden, MD, discusses the latest Cobenfy data and implications for schizophrenia treatment.

Transneural Therapeutics launches innovative neuroplastogens to revolutionize treatment for neuropsychiatric diseases, promising safer, effective alternatives to psychedelics.

Cobenfy as an adjunctive treatment to atypical antipsychotics did not reach the primary endpoint of the phase 3 ARISE trial, or a statistically significant difference compared with placebo with an atypical antipsychotic.

Cybin partners with Osmind to enhance mental health treatment access, focusing on innovative therapies for depression and anxiety disorders.

The first patient has been dosed in MindMed’s phase 3 Emerge study evaluating the efficacy of MM120 ODT.